2014
Body Mass Index and Acute and Long-Term Outcomes After Acute Myocardial Infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Trial)
Herrmann J, Gersh B, Goldfinger J, Witzenbichler B, Guagliumi G, Dudek D, Kornowski R, Brener S, Parise H, Fahy M, McAndrew T, Stone G, Mehran R. Body Mass Index and Acute and Long-Term Outcomes After Acute Myocardial Infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Trial). The American Journal Of Cardiology 2014, 114: 9-16. PMID: 24846807, DOI: 10.1016/j.amjcard.2014.03.057.Peer-Reviewed Original ResearchConceptsST-segment myocardial infarctionBody mass indexLong-term outcomesHigher body mass indexBMI quartilesMass indexMyocardial infarctionIschemia-driven target vessel revascularizationAcute Myocardial Infarction trialHigher-weight patientsLower cardiac mortalityLowest BMI quartileCardiovascular risk profileMajor bleeding eventsMyocardial Infarction trialTarget vessel revascularizationLong-term mortalityAcute cardiovascular eventsAcute myocardial infarctionLarge multinational cohortBleeding eventsHarmonizing OutcomesHospital mortalityMyocardial reinfarctionNoncardiac mortality
2011
Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial
Stone G, Witzenbichler B, Guagliumi G, Peruga J, Brodie B, Dudek D, Kornowski R, Hartmann F, Gersh B, Pocock S, Dangas G, Wong S, Fahy M, Parise H, Mehran R, Investigators O. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. The Lancet 2011, 377: 2193-2204. PMID: 21665265, DOI: 10.1016/s0140-6736(11)60764-2.Peer-Reviewed Original ResearchMeSH KeywordsAngioplasty, BalloonCombined Modality TherapyConfidence IntervalsDose-Response Relationship, DrugDrug Administration ScheduleDrug Therapy, CombinationDrug-Eluting StentsElectrocardiographyFemaleFollow-Up StudiesHeparinHirudinsHumansKaplan-Meier EstimateMaleMyocardial InfarctionPaclitaxelPeptide FragmentsPlatelet Glycoprotein GPIIb-IIIa ComplexProspective StudiesRecombinant ProteinsStentsSurvival AnalysisTime FactorsTreatment OutcomeConceptsST-segment elevation myocardial infarctionGlycoprotein IIb/IIIa inhibitorsPrimary percutaneous coronary interventionIIb/IIIa inhibitorsPercutaneous coronary interventionPaclitaxel-eluting stentsBare metal stentsBivalirudin monotherapyStent thrombosisCoronary interventionMyocardial infarctionIschaemia-driven target lesion revascularisationIschaemia-driven target vessel revascularisationMajor adverse cardiovascular eventsComposite adverse eventsHORIZONS-AMI trialPaclitaxel-eluting stentingTarget vessel revascularisationAdverse cardiovascular eventsBypass graft surgeryTarget lesion revascularisationElevation myocardial infarctionOnset of symptomsKaplan-Meier estimatesAcute myocardial infarction
2005
Obesity and the Risk of New-Onset Atrial Fibrillation—Reply
Wang T, Parise H, Sullivan L, D’Agostino R, Levy D, Wolf P, Vasan R, Benjamin E. Obesity and the Risk of New-Onset Atrial Fibrillation—Reply. JAMA 2005, 293: 1974-1975. PMID: 15855424, DOI: 10.1001/jama.293.16.1975-a.Peer-Reviewed Original Research